Michael Scordo

5.7k total citations
120 papers, 1.3k citations indexed

About

Michael Scordo is a scholar working on Oncology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Michael Scordo has authored 120 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Oncology, 55 papers in Hematology and 22 papers in Pathology and Forensic Medicine. Recurrent topics in Michael Scordo's work include CAR-T cell therapy research (35 papers), Multiple Myeloma Research and Treatments (28 papers) and Hematopoietic Stem Cell Transplantation (25 papers). Michael Scordo is often cited by papers focused on CAR-T cell therapy research (35 papers), Multiple Myeloma Research and Treatments (28 papers) and Hematopoietic Stem Cell Transplantation (25 papers). Michael Scordo collaborates with scholars based in United States, Spain and Italy. Michael Scordo's co-authors include Gunjan L. Shah, Craig S. Sauter, Miguel‐Angel Perales, Parastoo B. Dahi, Sean M. Devlin, Stephen W. Dusza, Emanuela Romano, Paul B. Chapman, Daniel G. Coit and Sergio Giralt and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Michael Scordo

104 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Scordo United States	17	834	272	251	229	161	120	1.3k
Bahru Habtemariam United States	12	480 0.6×	626 2.3×	176 0.7×	73 0.3×	202 1.3×	23	1.3k
Philipp B. Staber Austria	23	593 0.7×	804 3.0×	390 1.6×	395 1.7×	356 2.2×	88	1.9k
Luke P. Akard United States	21	403 0.5×	294 1.1×	691 2.8×	125 0.5×	157 1.0×	78	1.3k
Jing Cui China	20	237 0.3×	412 1.5×	100 0.4×	83 0.4×	75 0.5×	70	1.2k
Tarek H. Mouhieddine United States	18	457 0.5×	447 1.6×	230 0.9×	111 0.5×	93 0.6×	61	1.2k
Suwen Li China	13	367 0.4×	314 1.2×	131 0.5×	39 0.2×	171 1.1×	31	1.2k
Elizabeth J. Davis United States	17	740 0.9×	403 1.5×	49 0.2×	95 0.4×	217 1.3×	64	1.5k
Heleia Roca-Ho Spain	12	166 0.2×	158 0.6×	80 0.3×	41 0.2×	98 0.6×	21	648

Countries citing papers authored by Michael Scordo

Since Specialization

Citations

This map shows the geographic impact of Michael Scordo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Scordo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Scordo more than expected).

Fields of papers citing papers by Michael Scordo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Scordo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Scordo. The network helps show where Michael Scordo may publish in the future.

Co-authorship network of co-authors of Michael Scordo

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Scordo. A scholar is included among the top collaborators of Michael Scordo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Scordo. Michael Scordo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shah, Gunjan L., Tomalika R. Ullah, MM Hafeez, et al.. (2025). Infusional N-Acetylcysteine Enhances CAR T Cell Persistence in Patients with Aggressive B-Cell Lymphomas. Transplantation and Cellular Therapy. 31(2). S238–S239.

Imber, Brandon S., et al.. (2024). The Role of Radiotherapy in Lymphoma Patients Undergoing CAR T Therapy: Past, Present, and Future. Seminars in Radiation Oncology. 35(1). 99–109. 4 indexed citations

Dusza, Stephen W., et al.. (2024). Dermatologic Adverse Events Associated With Chimeric Antigen Receptor T-Cell Therapy: A Pharmacovigilance Analysis of the FDA Reporting System. Transplantation and Cellular Therapy. 30(10). 1035.e1–1035.e7. 2 indexed citations

Boelens, Jaap Jan & Michael Scordo. (2024). Model-based dosing for better survival after transplantation. Blood Advances. 8(23). 6064–6066.

Tringale, Kathryn R., Michael Scordo, Joachim Yahalom, et al.. (2024). Evolving consolidation patterns and outcomes for a large cohort of patients with primary CNS lymphoma. Blood Advances. 8(24). 6195–6206. 8 indexed citations

Tringale, Kathryn R., Christian Grommes, Anne S. Reiner, et al.. (2024). Consolidation Regimen and Cerebral Atrophy in Patients With Primary Central Nervous System Lymphoma. International Journal of Radiation Oncology*Biology*Physics. 121(5). 1248–1257. 1 indexed citations

Melica, Giovanna, Alejandro Luna, Gunjan L. Shah, et al.. (2024). Shift from Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T Cell Therapy: Results from a Large Retrospective Cohort. Transplantation and Cellular Therapy. 31(1). 36–44. 4 indexed citations

Cederquist, G., Kathryn R. Tringale, Carla Hajj, et al.. (2023). Salvage Radiotherapy as a Bridge for Relapsed Secondary CNS Lymphoma. International Journal of Radiation Oncology*Biology*Physics. 117(2). e459–e459. 1 indexed citations

Devlin, Sean M., Beatriz Wills, Amethyst Saldia, et al.. (2023). Comparison of Bendamustine Versus Fludarabine/ Cyclophosphamide Lymphodepletion in Adult Patients Receiving CD19 CAR-T Cell Therapy. Blood. 142(Supplement 1). 3510–3510. 1 indexed citations

10.

Derkach, Andriy, Billel Gasmi, Theodora Anagnostou, et al.. (2023). T-Cell Exhaustion Signature Predicts Early Relapse after Autologous Stem Cell Transplant for Multiple Myeloma: BMT CTN 0702 Secondary Immune Analysis. Blood. 142(Supplement 1). 3326–3326. 1 indexed citations

11.

Nath, Karthik, Samantha Brown, Sean M. Devlin, et al.. (2023). Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy. 30(1). 81–92.

12.

Park, Jae H., Karthik Nath, Sean M. Devlin, et al.. (2023). CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nature Medicine. 29(7). 1710–1717. 99 indexed citations

13.

Scordo, Michael, Leah Gilbert, Jessica Flynn, et al.. (2022). Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation. Blood Advances. 7(8). 1536–1544. 4 indexed citations

14.

Landau, Heather, Elizabeth Rodríguez, Allison J. Applebaum, et al.. (2022). Pilot Trial of Homebound Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 28(12). 832.e1–832.e7. 5 indexed citations

15.

Hultcrantz, Malin, Even H. Rustad, Venkata Yellapantula, et al.. (2022). Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma. Clinical Cancer Research. 28(10). 2160–2166. 1 indexed citations

16.

Shah, Nishi, Ana Alarcón Tomás, Josel D. Ruiz, et al.. (2021). High Rates of Residual Vaccine Titers at 1-Year Post CD19 Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy. 27(3). S355–S355. 3 indexed citations

17.

Khaled, Samer K., Jaap Jan Boelens, Mitchell S. Cairo, et al.. (2021). Narsoplimab (OMS721), a Masp-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA). Transplantation and Cellular Therapy. 27(3). S24–S26. 2 indexed citations

18.

Lumish, Melissa, Lorenzo Falchi, Brandon S. Imber, et al.. (2021). How we treat mature B-cell neoplasms (indolent B-cell lymphomas). Journal of Hematology & Oncology. 14(1). 5–5. 22 indexed citations

19.

Reidy‐Lagunes, Diane, Leonard B. Saltz, Michael A. Postow, et al.. (2020). Recommendations for Testing and Treating Outpatient Cancer Patients in the Era of COVID-19. JNCI Journal of the National Cancer Institute. 113(7). 820–822. 5 indexed citations

20.

Imber, Brandon S., M. Lia Palomba, Carl J. DeSelm, et al.. (2019). MSKCC Early Experience Using Radiotherapy As a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma before CD19 CAR T Therapy. Blood. 134(Supplement_1). 3238–3238. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bahru Habtemariam Breakdown of academic impact, for papers by Philipp B. Staber Breakdown of academic impact, for papers by Luke P. Akard Breakdown of academic impact, for papers by Jing Cui Breakdown of academic impact, for papers by Tarek H. Mouhieddine Breakdown of academic impact, for papers by Suwen Li Breakdown of academic impact, for papers by Elizabeth J. Davis Breakdown of academic impact, for papers by Heleia Roca-Ho